Terms: = Gastric cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
4 results:
1. OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome.
Pandian J; Panneerpandian P; Sekar BT; Selvarasu K; Ganesan K
Funct Integr Genomics; 2022 Dec; 22(6):1345-1360. PubMed ID: 35987846
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA MYLK-AS1 acts as an oncogene by epigenetically silencing large tumor suppressor 2 (LATS2) in gastric cancer.
Luo J; Xiang H
Bioengineered; 2021 Dec; 12(1):3101-3112. PubMed ID: 34181498
[TBL] [Abstract] [Full Text] [Related]
3. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.
Clermont PL; Fornaro L; Crea F
Epigenomics; 2017 Oct; 9(10):1329-1335. PubMed ID: 28875726
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of ezh2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract] [Full Text] [Related]
